(Original title: Chairman of the two listed companies talks about the internationalization of Li Shufu: Chinese cars account for a very low proportion of the global market)

On March 20th, the fifth "representative channel" of the first session of the 13th National People's Congress was opened. Nine deputies to the National People's Congress were interviewed. Chairman of Zhejiang Geely Holding Group Co., Ltd., Chairman of Volvo Car Corporation Li Shufu, and Chairman of Jiangsu Kangyuan Group Xiao Wei, represented the channel. The performance of Geely Automobile and Kangyuan Pharmaceuticals in the capital market also served as the face of the two presidents, both of which closed with the red line, and Kangyuan Pharmaceuticals soared 6.44%.

Zhejiang Geely Holding Group Chairman Li Shufu

In February of this year, Geely Group announced that it has acquired 9.69% of the voting shares of Daimler AG through its overseas corporate entities, valued at approximately US$9 billion. Will Chinese auto companies follow Li Shufu’s steps to quickly internationalize?

"Today, 50% and 60% of China's autos are foreign foreign brands. China's auto industry accounts for a very low proportion of the global market. How do you really achieve what you have and I have your competitive landscape, and we need to continue to promote the globalization process." Li Shufu said in response to a reporter’s question.

The internationalization of the automotive industry has attracted much attention. How Chinese traditional Chinese medicines go international has also received much attention.

In the process of Chinese medicine in the world, what are the current problems? Xiao Wei said that "up to now, none of our proprietary Chinese medicines have officially entered the international market as pharmaceuticals and have completed registration in the international community. This means that our proprietary Chinese medicines cannot enter the international mainstream pharmaceutical market as a drug."

Continue to promote the globalization of the automotive industry

How should China's auto industry focus on the mid-to-high end of the value chain? Li Shufu said that China’s auto industry is now at the middle and low end of the global value chain. How to move to the mid-to-high end is an important issue facing Geely.

Geely must continue to lay the foundation and practice internal strength. Secondly, it must create new kinetic energy, transform old kinetic energy, and finally achieve a complete switch between old and new kinetic energy. Li Shufu said: “Increase investment in talent training and increase R&D and innovation capacity. Geely has a number of innovative R&D capability centers around the world. Currently, Ningbo, Zhejiang, is building large-scale innovation and R&D capability centers in Ningbo, which is Geely. A very typical place for cars to develop in high quality."

“The 21st century is a period of scientific and technological revolution, industrial transformation, and commercial reshaping. During this period, online digital technology research is very important. Geely wants to form an online service capability as soon as possible. The future automobile is highly integrated online and offline. Smart space mobile terminals, so to provide users with space across the era of highly integrated online and offline mobile terminal products, allowing users to experience the smart space mobile terminal brings the consumer experience.” Li Shufu said, this requires Geely to add Big investment in digital technology.

To continue to increase the construction of electrification, automobile electrification is the trend. For this reason, Geely formulated the "Blue Action" plan, and by 2020, more than 90% of Geely's automotive products are new energy vehicles. Li Shufu particularly values ​​electric cars.

Globalization requires China to constantly increase its global market share, continuously increase product added value and brand influence, and at the same time adopt global market supervision. Li Shufu said: “We must continue to promote the process of globalization. The real thing is that you have me and me. With your competitive landscape, this will require continuing the globalization process."

The internationalization of proprietary Chinese medicines is still a long way

“So far, none of our proprietary Chinese medicines have officially entered the international market as pharmaceuticals and have completed registration in the international community. This means that our proprietary Chinese medicines cannot enter the international mainstream pharmaceutical market as a drug, and Chinese medicine is internationalized. The road is still very long.” Xiao Wei said that in recent years, China’s Chinese medicine industry has been developing very well, with a scale of nearly trillion yuan. However, although the situation of Chinese medicine in China is very good, it is not optimistic at the international level.

In the process of Chinese medicine going to the world, what problems still exist? Xiao Wei said that the Chinese medicine industry has long been highly concerned by the party and the country. The Nineteenth National Congress proposed to support the development of traditional Chinese medicine and adhered to the development requirements of both Chinese and Western medicine. The development of Chinese medicine has formed a favorable situation in recent years. The people's excellent situation.

"The road to internationalization of Chinese medicine in China is still very long. There are four main reasons." Xiao Wei further analyzed that the first is the theoretical difference between Chinese and Western medicine is relatively large; the second is that Chinese medicine itself is a medicine, it is medicine should be It is consistent with the drug's safe, effective and uniform quality and controllable drug properties. However, currently, some natural products originate from traditional Chinese medicines. The complexity is far more complex than that of chemical drugs, and it also restricts uniformity and safety and effectiveness. Third, it is to upgrade the advanced level of manufacturing. After the establishment of an important system standard, the improvement of the manufacturing level is very important; the fourth is to encourage Chinese patent medicines to be registered in the international market. It is a large-cost, high-cycle, long-term project. Not all companies are willing to go. made. "I think that the state and society should encourage and support these companies to go out and succeed."

"Since 1999, Kangyuan Pharmaceuticals has started the international registration of medicines. It has now lasted 18 years. It takes an estimated three years or so to obtain an international registration in the United States. Now the progress is smooth." Said.

Xiao Wei said that the internationalization of Chinese medicine should really set standards for the formation of Chinese medicine. “Not that Chinese medicine has no standards at present. There is still a gap between our standards for Chinese medicine and internationalization. We must form a therapeutic effect and evaluate these standards in the therapeutic field of Chinese patent medicines. set up."

Xiao Wei suggested that it is necessary to establish a series of standard systems from raw materials to production processes to finished products. The establishment of standardization of traditional Chinese medicine is very important for satisfying the establishment of international drug registration standards.